Statement of Changes in Beneficial Ownership (4)
May 05 2020 - 4:29PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Onopchenko John |
2. Issuer Name and Ticker or Trading Symbol
ENDOLOGIX INC /DE/
[
ELGX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO and Director |
(Last)
(First)
(Middle)
2 MUSICK |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/2/2020 |
(Street)
IRVINE, CA 92618
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 5/2/2020 | | A | | 60443 (1) | A | $0 | 270568 | D | |
Common Stock | 5/2/2020 | | F | | 6968 (2) | D | $0.8879 | 263600 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. 33% percent of the shares subject to this restricted stock unit award vested pursuant to the terms of this award. |
(2) | Shares withheld on May 2, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on May 2, 2020. |
Remarks: The reporting person's beginning share balance includes a number of shares issued under the company's Employee Stock Purchase Plan not previously reported to the Securities and Exchange Commission as the number of shares was deemed immaterial by the company. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Onopchenko John 2 MUSICK IRVINE, CA 92618 | X |
| CEO and Director |
|
Signatures
|
John Onopchenko by Timothy N. Brady Attorney-in-Fact for Reporting Person | | 5/5/2020 |
**Signature of Reporting Person | Date |
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024